[Articles] Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
In adults with obesity or overweight without diabetes (type 1 or 2), individuals administered ecnoglutide had superior and sustained reduction in bodyweight versus placebo with a favourable safety profile, supporting its potential use for weight management.
[Comment] Is biased agonism helpful in the treatment of obesity with the GLP-1 receptor analogues?
Obesity, overweight, and the consequences of excess adiposity continue to drive a substantial proportion of morbidity and mortality around the world. Prevention and treatment of obesity is an important strategy for preventing the development of multimorbidity.1 GLP-1 receptor monoagonists such as semaglutide2 or GLP-1 and glucose-dependent insulinotropic peptide (GIP) receptor multiagonists such as tirzepatide3 are […]